zoledronic acid (aclasta)
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Avascular Necrosis of Femoral Head
Conditions
Avascular Necrosis of Femoral Head
Trial Timeline
Jul 1, 2009 → Jun 1, 2012
NCT ID
NCT00939900About zoledronic acid (aclasta)
zoledronic acid (aclasta) is a phase 3 stage product being developed by Novartis for Avascular Necrosis of Femoral Head. The current trial status is completed. This product is registered under clinical trial identifier NCT00939900. Target conditions include Avascular Necrosis of Femoral Head.
What happened to similar drugs?
0 of 3 similar drugs in Avascular Necrosis of Femoral Head were approved
Approved (0) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00939900 | Phase 3 | Completed |
Competing Products
4 competing products in Avascular Necrosis of Femoral Head
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KW-3357 | Kyowa Kirin | Phase 3 | 40 |
| KW-3357 | Kyowa Kirin | Phase 3 | 32 |
| KW-3357 + Plasma-derived antithrombin | Kyowa Kirin | Phase 3 | 40 |
| BAY 3389934 + Matching Placebo / Diluent | Bayer | Phase 1 | 33 |